Glycotope will present new data on antibodies and fusion proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) meeting

Glycotope will present new data on antibodies and fusion proteins against GlycoTargets at the 2022 American Association for Cancer Research (AACR) meeting

Berlin, Germany, 08 April2022Glycotop GmbHa biotechnology company developing antibodies against proteins bearing tumor-specific carbohydrate structures, today announced that it will present new data at the 2022 American Association for Cancer Research (AACR) Annual Meeting, being held August 8-16 in New Orleans, USA, will take place in April 2022.

Patrik Kehler, Chief Scientific Officer of Glycotope GmbH, comments: “The data presented at AACR demonstrate the potential of targeting GlycoTargets to increase tumor selectivity of antibodies. We will present two anti-GlycoTarget antibodies with significantly improved tumor selectivity compared to protein-binding antibodies, resulting in decreased binding to healthy tissue or blood cells. In addition, we will present updated in vivo potency data for GT-00A x IL15, our TA-MUC1-targeted IL-15 fusion antibody. GT-00A x IL15 is one of the first tumor-targeted immune cytokines and has the potential to significantly outperform non-targeted IL-15 immune cytokines, providing a much-needed alternative in the treatment of multiple solid tumor indications.”

Poster details are as follows:

Abstract number: 4542 Download here starting Friday, April 8th 1pm ET / 7pm BST

Title: Carbohydrate-dependent protein-binding antibodies with superior tumor specificity

Category: Poster Section 21: Antibodies and Immunotherapies

Session start time: 04/10/2022 1:30 p.m

session end time: 04/10/2022 17:00:00

Abstract number: 4584 Download here starting Friday, April 8 at 1pm ET / 7pm BST

Abstracts are now available on the AACR website at www.aacr.org. E-posters will be available to registrants at the AACR Annual Meeting on Friday, April 8 at 1:00 pm EDT

Title: Preclinical Characterization of GT-00A x IL15: A Novel IL-15-Based Immunocytokine with Unique Tumor Targeting Properties

Category: Poster Section 37: Therapeutic Antibodies 1

Session start time: 04/12/2022 09:00:00

session end time: 04/12/2022 12:30:00 p.m

Contact information:





Glycotop GmbH
dr Patrick Kehler
CSO
Telephone: +49 30 9489 2600
Email: [email protected]

Media contact:
Chris Gardner, Chris Welsh
Consilium Strategic Communication
Telephone: +44 (0) 20 3709 5700
Email: [email protected]

About GT-00A x IL15

GT-00A x IL15 is an IL-15 immunocytokine fusion antibody targeted to TA-MUC1. Cytokines have long been used in cancer therapy to activate the immune system, but side effects and a short half-life limit their therapeutic use. The concept of specifically targeting the tumor and tumor microenvironment to realize the full potential of IL-15 biology is unique in the competitive arena of IL-15 (super)agonists. The immune cytokine attracts and activates immune cells (e.g. T and NK cells) directly at the tumor site, turning an “immune desert” into a “hot” tumor and inducing tumor cell lysis. A comprehensive non-clinical data package is available.

About Glycotopee

Glycotope is a biotechnology company using a proprietary technology platform to develop unique tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or protein/carbohydrate combined glycoepitopes (GlycoTargets). To date, Glycotope has discovered more than 130 GlycoTargets with antibodies against several of these targets that are currently in development.

Because of their superior tumor specificity, our antibodies are suitable for development in a range of different modes of action, including naked antibodies, bispecific antibodies, antibody-drug conjugates, cell therapies, or fusion proteins.

Visit www.glycotope.com


Comments are closed.